Alnylam Pharmaceuticals · 8 months ago
Scientist, Investigative Sciences
Cambridge, MA
Full-time
Onsite
Mid Level
$110K/yr - $166K/yr
1+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, seeking a scientist to advance their RNAi therapeutics platform. The role involves elucidating mechanisms of toxicity and conducting toxicological evaluations of siRNA ligands to support candidate selection and transition to early development.
BiotechnologyHealthcarePharmaceuticalHealth CareMedicalTherapeutics
No H1B
Responsibilities
Design and execute hypothesis-driven mechanistic in vitro studies to investigate toxicity findings
Development and optimization of in-house in vitro models to support RNAi platform and novel ligand candidate derisking. Working with external vendors on technology and assay evaluation, where appropriate, also expected
Assess and implement new technologies to support/improve compound toxicity prediction & screening. Preference toward high-throughput or genomics platforms
Collaborate closely with discovery scientists, toxicologists, and pathologists to deconvolute toxicology issues and ensure strategic investigative alignment for candidate selection
Communicate study rationale, results, and recommendations through high-quality reports, presentations, and cross-functional meetings
Maintain high standards of scientific rigor, data integrity
Qualification
Required
Ph.D. degree in Immunology, Molecular Toxicology, Pharmacology, or related field
Demonstrated knowledge in designing and conducting in vitro mechanistic studies
Technical proficiency in standard cellular and molecular biology techniques
Must be a highly motivated and organized individual with team orientated mentality and enjoy working in fast-paced and collaborative environment
Excellent written and oral communication skills
Preferred
1-3 years relevant experience in academia or industry is preferred
Experience with microphysiological systems (i.e. organ-on-chip, organoids, or iPSC models) is desired
Experience with high-content imaging and/or flow cytometry preferred
Experience with modalities such as small molecules and biologics preferred
Benefits
This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity).
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k)with a generous company match
Eligible employees enjoy paid time off
Wellness days
Holidays
Two company-wide recharge breaks
We also offer generous family resources and leave.
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Company data provided by crunchbase